^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Fusions in ALK and ROS1, more common in lung cancer, occur uncommonly (>1% incidence) across subtypes of melanoma
Fusions in these genes may predispose to clinical activity from inhibitors of these genes (eg, crizotinib and entrecitinib).
